Evolus (NASDAQ:EOLS) and Jin Medical International (NASDAQ:ZJYL) Head-To-Head Survey

Evolus (NASDAQ:EOLS) and Jin Medical International (NASDAQ:ZJYL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, profitability and earnings.

Profitability

This table compares Evolus and Jin Medical International’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evolus	-14.39%	N/A	-19.03%
Jin Medical International	N/A	N/A	N/A

Valuation & Earnings

This table compares Evolus and Jin Medical International”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evolus	$297.18 million	1.49	-$51.64 million	($0.67)	-10.06
Jin Medical International	$20.69 million	0.92	$1.19 million	N/A	N/A

Jin Medical International has lower revenue, but higher earnings than Evolus.

Risk and Volatility

Evolus has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500. Comparatively, Jin Medical International has a beta of 7.23, suggesting that its share price is 623% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Evolus and Jin Medical International, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evolus	1	1	4	0	2.50
Jin Medical International	1	0	0	0	1.00

Evolus currently has a consensus price target of $16.00, suggesting a potential upside of 137.39%. Given Evolus’ stronger consensus rating and higher probable upside, analysts clearly believe Evolus is more favorable than Jin Medical International.

Institutional & Insider Ownership

90.7% of Evolus shares are held by institutional investors. 5.0% of Evolus shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Evolus beats Jin Medical International on 7 of the 11 factors compared between the two stocks.

About Evolus

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

About Jin Medical International

Jin Medical International Ltd. engages in the design, development, manufacturing, and sale of wheelchair and other living aids products for people with disabilities or impaired mobility in China and internationally. It also offers oxygen concentrators and bathing machines. The company was founded in 2006 and is based in Changzhou, China. Jin Medical International Ltd. is a subsidiary of Jolly Harmony Enterprises Limited.